Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
04/2008
04/16/2008EP1910361A2 Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
04/16/2008EP1910359A1 PYRIDO [2 , 3-D]PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS
04/16/2008EP1910352A1 Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
04/16/2008EP1910350A1 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
04/16/2008EP1910344A2 Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments
04/16/2008EP1910340A1 Indazolecarboxamide derivatives as 5ht4 receptor agonists
04/16/2008EP1910339A2 Azepane- or azocane-substituted pyrazoline derivatives, their preparation and use as medicaments
04/16/2008EP1910332A2 Substituted pyrazoline compounds, their preparation and use as medicaments
04/16/2008EP1910331A1 PYRAZOLE DERIVATIVES AS CBl MODULATORS
04/16/2008EP1910321A1 New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson's disease
04/16/2008EP1910310A1 Novelimidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
04/16/2008EP1910308A1 Imidazole based lxr modulators
04/16/2008EP1910307A1 Pyrazole based lxr modulators
04/16/2008EP1910302A1 Carbonyl substituted pyrazoline compounds, their preparation and use as cb1 receptor modulators
04/16/2008EP1910301A2 Cycloalkane-substituted pyrazoline derivatives, their preparation and use as medicaments
04/16/2008EP1910300A2 Prodrugs of pyrazoline compounds, their preparation and use as medicaments
04/16/2008EP1910294A1 A process for the preparation of substituted phenyl ether compounds and rosiglitazone
04/16/2008EP1910290A2 Gpcr agonists
04/16/2008EP1910274A1 Phenyl compounds
04/16/2008EP1909912A2 Use of collismycin and derivatives thereof as oxidative stress inhibitors
04/16/2008EP1909910A1 Benzimidazole derivatives as sirtuin modulators
04/16/2008EP1909818A2 Use of bpi protein for treatment of diseases
04/16/2008EP1909802A2 Steroidal glycoside compounds as core 2 glcnac-t inhibitors
04/16/2008EP1909793A2 Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors
04/16/2008EP1909791A1 G-protein coupled receptor agonists
04/16/2008EP1909789A2 Antidiabetic oxazolidinediones and thiazolidinediones
04/16/2008EP1476032B1 Coenzyme q10 formulation
04/16/2008EP1440059B1 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists
04/16/2008EP1423382B1 Pyrazole-derived kinase inhibitors and uses thereof
04/16/2008EP1108039B1 Elongase genes and uses thereof
04/16/2008CN101163668A Calcium bis [ (2s) - 3- [3-[ (2s) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
04/16/2008CN101163520A Method for lengthening the seasonal mobility period of fish
04/16/2008CN101163504A 联合疗法 Combination therapy
04/16/2008CN101161677A Recombinant polypeptide having islets beta- cell protection function
04/16/2008CN101161641A Tricyclic steroid hormone nuclear receptor modulators
04/16/2008CN101161270A Pharmaceutical composition of cattail pollen and kudzu root
04/16/2008CN101161268A Pharmaceutical composition of red sage root and cattail pollen
04/16/2008CN101161247A Potassium muriate stomach-inner retention floationg type slow release tablet prepared with shuck powder as carrier
04/16/2008CN100381454C Crystalline form of a ribofuranosyluronamide derivative: a human adenosine a2a receptor agonist
04/16/2008CN100381438C New pyrrolidine and thiazolidine compounds, process for their preparation and pharmaceutical compositions containing them
04/16/2008CN100381150C Composition comprising epalrestat
04/16/2008CN100381132C Hypoglycemic Chinese medicine prepn and its production process
04/16/2008CN100381131C Bee pollen soft capsule and preparation method thereof
04/16/2008CN100381130C Bee pollen nutrition oral liquid and preparation method thereof
04/16/2008CN100381119C Compositions for diabetes
04/16/2008CN100381063C Preparation method of fat-reducing blood sugar-reducing sour soybean milk containing micro gingko leaf, Gymostamma pentaphyllum, haw and konnjaku powder
04/15/2008US7358386 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
04/15/2008US7358354 Administering genetically engineered vectors to modulate lymphocytes; transfecting macrophages; used for prophylaxis or treatments for cancers or immune-related disorders
04/15/2008US7358342 Preparation derived from shark cartilage for treatment of diseased related to excessive PHF or excessive intracellular calcium
04/15/2008US7358341 Secreted protein for use in diagnosis, prevention and treatment of thyroid gland disorders
04/15/2008US7358338 Heme peptide
04/15/2008US7358333 Polypeptides of the IFNα-5 gene
04/15/2008US7358253 Indolylmaleimide derivatives
04/15/2008US7358252 Psychological disorders; central nervous system disorders; antidepressants; anxiolytic agents; stress reliever
04/15/2008US7358248 treatment of diabetes and/or cancer; useful in the treatment of syndrome X; capable of inhibiting Protein tyrosine phosphatases
04/15/2008US7358242 N-benzyl-2-[4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-2,3,6,10b-tetraaza-benzo[e]azulen-6-yl]-N-isopropyl-acetamide; cholecystokinin-A (CCK-A) receptor agonist; antidiabetic; obesity
04/15/2008US7358238 3-(2-Phenoxymethyl-phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]azepin-9-one; inhibiting the activity of 11 beta -hydroxysteroid dehydrogenase type 1 (11 beta HSD1); increase intracellular concentration of active glucocorticoid; metabolic disorders, insulin resistance, dyslipidemia, obesity
04/15/2008US7357924 Nucleic acids/proteins/antibodies/mimetics for cell differentiation/prolilferation control
04/15/2008CA2410985C Compositions and methods for body weight management
04/15/2008CA2405265C Method of preventing or treating diabetes
04/10/2008WO2008042892A2 Fatty acid amide hydrolase inhibitors for energy metabolism disorders
04/10/2008WO2008042223A1 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
04/10/2008WO2008041665A1 Screening method for prophylactic and/or therapeutic agent for disease accompanied by hepatitis c
04/10/2008WO2008041236A2 Composition comprising crustacean gastrolith components, calcium carbonate and its use
04/10/2008WO2008041090A1 Malanin concentrating hormone receptor-1 antagonist pyridinones
04/10/2008WO2008041049A1 Cinnamomum zeylanicum plant extracts for the treatment of diabetes and the extraction process thereof
04/10/2008WO2008041003A2 Hydroxycholesterols and its prodrugs for the treatment of insulin resistance and disorers asociated therewith
04/10/2008WO2008040995A1 Indazoles for use as dpp-iv inhibitors
04/10/2008WO2008040979A1 Arginine derivatives with np-i antagonistic activity
04/10/2008WO2008040548A2 Treatment for non-alcoholic-steatohepatitis
04/10/2008WO2008040192A1 13,13a-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE
04/10/2008WO2008040057A1 Novel benzofuran potassium channel blockers and uses thereof
04/10/2008WO2008017752A3 Eucalyptus extract, method of preparation and therapeutic uses thereof
04/10/2008WO2008005569A3 Modulators of metabolism and the treatment of disorders related thereto
04/10/2008WO2007149451B1 Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
04/10/2008WO2007144394A3 Pharmaceutical use of substituted piperidine carboxamides
04/10/2008WO2007125105A3 Benzamide glucokinase activators
04/10/2008WO2007125103A3 Benzamide glucokinase activators
04/10/2008WO2007100833A3 Gpat4 encodes a mammalian, microsomal acyl-coa:glycerol 3-phosphate acyltransferase
04/10/2008WO2007098240A3 Compositions to reduce blood glucose levels and treat diabetes
04/10/2008WO2007092469A3 Combination of organic compounds
04/10/2008US20080086000 Prostaglandin reductase
04/10/2008US20080085928 such as N,N'-[hexane-1,6-diylbis(iminocarbonyl)]bis(3-chlorobenzenesulfonamide), used as Fructose-1,6-bisphosphatase inhibitors; metabolic disorders such as diabetes
04/10/2008US20080085926 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
04/10/2008US20080085911 Utilization of HMG-CoA inhibitors and omega-3 fatty acids for reduction of Apo-B levels beyond those obtained with treatment of HMG-CoA inhibitor alone; especially useful for treatment of hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, vascular disease, atherosclerotic disease
04/10/2008US20080085909 Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one
04/10/2008US20080085897 Inhibitors of cyclic guanosine monophosphate-metabolizing phosphodiesterases (cGMP PDE); cardiac insufficiency, cancer, bladder disorders, or prostate hyperplasia; 2-[2-ethoxy-5-(4-methyl-piperazine-1-sulphonyl)-phenyl]-5,7-dimethyl-3H-imidazo-[5,1-f]-[1,2,4]triazin-4-one for example
04/10/2008US20080085890 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof
04/10/2008US20080085887 Hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy; e.g. (R)-3-(1-(3,4-difluorophenyl) propan-2-yl)-2-(3-hydroxypyridin-2-yl) 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one
04/10/2008US20080085884 Eating disorders, psychological disorders, sexual disorders, nervous system disorders, sleep disorders, autism; 4-(Benzyloxy)-6'-[3-methyl-3-(methylamino)pyrrolidin-1-yl]-2H-1,3'-bipyridin-2-one for example
04/10/2008US20080085883 Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
04/10/2008US20080085873 Disease treatment methods
04/10/2008US20080085872 Administering colesevelam hydrochloride, and an antihyperlipidemic agent; a plasma HDL-raising agent; an antihypercholesterolemic agent; an acyl-coenzyme A: a cholesterol acyltransferase (ACAT) inhibitor; a cholesterol absorption inhibitor; a bile acid sequestrant anion exchange resin
04/10/2008US20080085864 Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
04/10/2008US20080085860 Selective Vpac2 Receptor Peptide Agonists
04/10/2008US20080085332 Via Cissus quadrangularis plant extracts; for reduction of body weight and controlling cholesterol levels
04/10/2008US20080085306 Topiramate compositions and methods of enhancing its bioavailability
04/10/2008US20080085298 administering insulin, a dissolution agent and a zinc chelator to a mucosal surface, preferably the mouth or under the tongue; enhanced uptake and transport through epithelial cells as compared to insulin alone or with a zinc chelator and hydrochloric acid in a gel, film, powder or patch; stability
04/10/2008US20080085292 Composite Scaffolds Seeded with Mammalian Cells
04/10/2008US20080085259 Amine condensation polymers as phosphate sequestrants
1 ... 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 ... 1298